Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | F10 | P00742 | 5/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.41 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502572 | 0.95 | SMN1; SMN2 (0.60) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL6488351 | 0.93 | SMN1; SMN2 (0.53) | SMN1; SMN2RAB9ANPC1LMNATP53 | |
| SCHEMBL6489237 | 0.91 | MAPT (0.46) | SMN1; SMN2RAB9ANPC1LMNATP53 | |
| SCHEMBL6498339 | 0.89 | SMN1; SMN2 (0.51) | SMN1; SMN2RAB9ANPC1LMNATP53 | |
| SCHEMBL6502718 | 0.89 | MAPT (0.44) | SMN1; SMN2LMNATP53MAPTTAS1R3 | |
| SCHEMBL6501410 | 0.88 | SMN1; SMN2 (0.60) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL6490142 | 0.87 | POLB (0.43) | RAB9ANPC1LMNATP53MAPT | |
| SCHEMBL6499318 | 0.86 | MAPT (0.49) | SMN1; SMN2RAB9ANPC1TP53MAPT | |
| SCHEMBL6500632 | 0.85 | ITGB1 (0.44) | TP53MAPTTAS1R3TAS1R1F10 | |
| SCHEMBL6497776 | 0.84 | GCGR (0.49) | SMN1; SMN2RAB9ANPC1LMNATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | SMN1; SMN2 1921/4885RAB9A 4382/4885NPC1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.